Remarkably, the authors performed CRISPR activation of LIMIT in a B16 melanoma model, which characteristically lacks responsiveness to PD-L1 blockade, and demonstrated resensitization of the tumor to anti-PD-L1 therapy. This evidence concerns the gene CD274 and neoplasm.